Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix H1 2026 Results: Investor Webcast Notification Melbourne (Australia) and Indianapolis, IN (U.S.) – July 31, 2026 . Telix...
Telix H1 2026 Results - Investor Webcast Notification
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
- Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
- Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
- Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Later from Telix Pharmaceuticals
- Telix to Host R&D Day in New York City on September 22, 2026
- Telix HY26 Appendix 4D and Interim Report
- Telix HY26 Results Announcement
- Telix HY26 Results Presentation
- Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals
